$KOD

BORGESON JOHN A. sold $881K of KOD

BORGESON JOHN A. (Chief Financial Officer) sold 25,896 shares of Kodiak Sciences Inc. (KOD) at $34.01 ($0.88M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · BORGESON JOHN A.
Published Jun 5, 2026, 9:56 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 5, 2026, 10:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$KOD
Neutral
medium confidence
Mentioned
$KOD
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KODNeutralLow
01

Why it matters

The disclosure updates the insider activity record; without additional company-specific news (earnings, trial, deal, guidance), it is unlikely to reset valuation expectations.

02

Market read

Provides a fresh insider-selling datapoint for KOD, but the 10b5-1 framing suggests limited incremental information.

03

What to watch

Traders should check whether there were multiple consecutive insider sales/buys around the same period; a single Form 4 is often not decisive.

Relevance 6/10Novelty 3/10Timing: SEC filing posted today (2026-06-05) for a sale executed 2026-06-04

Background

This is an SEC Form 4 insider transaction disclosure for Kodiak Sciences (KOD), filed after the CFO executed an open-market sale.

Company-level read

Ticker impact

$KODNeutralMedium confidence
Context

Kodiak Sciences CFO John A. Borgeson sold 25,896 shares (~$880.7K) via an open-market transaction under a 10b5-1 plan.

Expected impact

Near-term impact likely limited; any reaction may be sentiment-driven rather than fundamentals.

Evidence & confidence

Form 4 provides a concrete datapoint, but the transaction is explicitly under a pre-arranged 10b5-1 plan, which typically reduces interpretability as a new bearish thesis.

Market effects

Minimal; single-company insider transaction without accompanying operational/regulatory catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity rather than a change in outlook.

Key entities

  • Kodiak Sciences Inc.

    Subject of the Form 4 insider transaction; CFO sold shares under a 10b5-1 plan.

  • John A. Borgeson

    Chief Financial Officer who executed the open-market sale.

Related articles